Monthly urology bulletin — November 6, 2026
Period covered: October 7 to November 6, 2026. The month was dominated by the ESMO Congress (Madrid, October 23–27), with one positive and one negative trial in muscle-invasive bladder cancer (MIBC) and long-term survival data in metastatic prostate cancer. We include 5 verified items. We found no verifiable items from the period in stones and endourology or in andrology, transplantation, pediatric urology and robotic surgery.
Uro-oncology
1. VOLGA: perioperative durvalumab + enfortumab vedotin improves EFS and OS in cisplatin-ineligible MIBC
[Congress] [International]
Open-label phase 3 trial (NCT04960709), funded by AstraZeneca, presented at ESMO 2026 and published in NEJM: 695 patients with MIBC who were cisplatin-ineligible or declined cisplatin, randomized 1:1:1 to neoadjuvant durvalumab + enfortumab vedotin (D+EV), radical cystectomy and adjuvant durvalumab; the same regimen plus tremelimumab (D+T+EV); or radical cystectomy with or without approved adjuvant treatment. With D+EV, event-free survival improved (HR 0.51; 95% CI 0.38–0.67; P<.0001; median not reached vs 12.1 months), as did overall survival (HR 0.58; 95% CI 0.40–0.83; P=.0027; 24-month OS 78% vs 69%); centrally reviewed pathologic complete response 40% vs 8%. The triplet improved EFS (HR 0.61) but not OS (HR 0.77; P=.12) and was more toxic (treatment-related grade 3–4 adverse events in the presentation: 42% with the triplet vs 30% with D+EV; grade ≥3 in the publication: 44.5% vs 30.7%; 5 treatment-related deaths vs 1).
Why it matters: this is a perioperative regimen with an overall survival benefit in the cisplatin-ineligible population, a large group in our practice; it is an interim analysis of an AstraZeneca trial, and the FDA, which granted Priority Review, expects to act in the fourth quarter of 2026, according to the manufacturer's release. Access in the Dominican Republic will be limited by cost.
Sources
- [Article] Powles T, et al. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2608323. https://www.nejm.org/doi/full/10.1056/NEJMoa2608323
- [Coverage] OncLive, October 24, 2026. https://www.onclive.com/view/durvalumab-plus-enfortumab-vedotin-improves-survival-in-cisplatin-ineligible-mibc
- [Official release] AstraZeneca, May 14, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/imfinzi-ev-improves-efs-os-in-bladder-cancer.html
- [Official release] AstraZeneca, September 25, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/perioperative-imfinzi-plus-neoadjuvant-enfortumab-vedotin-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html
- [Official release] AstraZeneca, October 24, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/perioperative-imfinzi-plus-neoadjuvant-enfortumab-vedotin-reduced-risk-of-recurrence-by-49-and-risk-of-death-by-42-in-muscle-invasive-bladder-cancer.html
- [Coverage] The ASCO Post, November 2026. https://ascopost.com/news/november-2026/phase-iii-volga-trial-explores-outcomes-in-muscle-invasive-bladder-cancer/
2. KEYNOTE-866: adding perioperative pembrolizumab to neoadjuvant gemcitabine–cisplatin did not significantly improve event-free survival
[Congress] [International]
Double-blind phase 3 trial presented at ESMO 2026 (abstract 4735O) and published in Annals of Oncology: 907 cisplatin-eligible MIBC patients randomized to pembrolizumab or placebo with neoadjuvant gemcitabine-cisplatin, radical cystectomy, and adjuvant pembrolizumab or placebo. EFS did not improve significantly (HR 0.88; 95% CI 0.71–1.10) and OS was similar (HR 1.00; 95% CI 0.79–1.27; not formally tested), despite a numerically higher pathologic complete response rate (44.4% vs 35.8%; not formally tested). The ENERGIZE trial (CA017-078; perioperative nivolumab + neoadjuvant gemcitabine-cisplatin), presented at the same meeting, also missed both co-primary endpoints, pathologic complete response and EFS (HR 0.94; P=.67).
Why it matters: it suggests that a higher pathologic complete response rate is not an adequate surrogate for survival; in cisplatin-eligible patients, cisplatin-based neoadjuvant chemotherapy remains the accessible standard while enfortumab vedotin–based regimens reshape the field.
Sources
- [Article] Bedke J, Arkosy P, Nishiyama H, et al. «Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study». Ann Oncol. 2026. DOI: 10.1016/j.annonc.2026.10.106. https://pubmed.ncbi.nlm.nih.gov/42918422/
- [Coverage] OncLive, October 23, 2026. https://www.onclive.com/view/pembrolizumab-plus-chemo-misses-efs-end-point-in-cisplatin-eligible-mibc
- [Coverage] CancerNetwork, October 23, 2026. https://www.cancernetwork.com/view/perioperative-pembrolizumab-plus-chemo-does-not-significantly-improve-efs-in-mibc
- [Meeting] ESMO Congress 2026, abstract 4736O (ENERGIZE), reproduced on the EAU UroOnco website. https://bladder.uroonco.uroweb.org/publication/results-from-a-phase-3-trial-of-neoadjuvant-chemotherapy-alone-vs-in-combination-with-nivolumab-followed-by-postsurgical-adjuvant-nivolumab-in-patients-with-muscle-invasive-bladder-cancer/
- [Coverage] OncLive (ENERGIZE), October 23, 2026. https://www.onclive.com/view/perioperative-nivolumab-plus-neoadjuvant-chemotherapy-misses-co-primary-end-points-in-mibc
- [Coverage] Urology Times, October 23, 2026. https://www.urologytimes.com/view/adding-perioperative-pembrolizumab-chemotherapy-does-not-improve-efs-mibc
3. PEACE-1 at nearly 8 years: the abiraterone benefit in de novo metastatic prostate cancer persists
[Congress] [France / Europe]
Long-term survival analysis of the phase 3 PEACE-1 trial (1,173 patients with de novo metastatic castration-sensitive prostate cancer; 2×2 factorial design testing abiraterone and prostate radiotherapy on top of ADT with or without docetaxel), presented at ESMO 2026 (abstract 2215O). At a median follow-up of 7.7 years, abiraterone improved OS in the overall population (HR 0.75; 95% CI 0.65–0.87; P=.0001) and in the ADT + docetaxel subgroup, n=710 (HR 0.68; median 6.2 vs 4.4 years; 8-year OS 40.3% vs 27.1%). The interaction by disease volume was not significant (P=.56); the estimate in low-volume disease was imprecise.
Why it matters: it supports triplet therapy (ADT + docetaxel + an androgen receptor pathway inhibitor), without the data supporting a different benefit by disease volume; generic abiraterone is one of the most affordable options in our setting.
Sources
- [Meeting] ESMO Congress 2026 (Madrid, October 23–27, 2026), abstract 2215O, publicly available on the EAU UroOnco website. https://prostate.uroonco.uroweb.org/publication/long-term-overall-survival-with-abiraterone-acetate-plus-prednisone-in-the-peace-1-phase-3-trial-for-de-novo-metastatic-castration-sensitive-prostate-cancer/
- [Coverage] CancerNetwork, October 25, 2026. https://www.cancernetwork.com/view/abiraterone-shows-durable-survival-benefit-in-de-novo-metastatic-cspc
- [Coverage] ecancer, October 24, 2026. https://ecancer.org/en/news/29089-esmo-2026-adding-abiraterone-to-adt-and-docetaxel-improves-survival-in-metastatic-prostate-cancer
- [Coverage] The ASCO Post, October 26, 2026. https://ascopost.com/news/october-2026/triplet-therapy-with-abiraterone-improves-os-long-term-in-metastatic-castration-sensitive-prostate-cancer/
4. CAPItello-281: descriptive overall survival analysis numerically favored capivasertib
[Congress] [International]
An updated, descriptive OS analysis of the phase 3 CAPItello-281 trial was presented at ESMO 2026 (1,012 men with PTEN-deficient metastatic hormone-sensitive prostate cancer; capivasertib + abiraterone vs placebo + abiraterone, with prednisone or prednisolone and androgen deprivation therapy in both arms), the basis of the June 12, 2026 FDA approval on radiographic PFS (median 33.2 vs 25.7 months; HR 0.81). At this ad hoc data cutoff, with 42% maturity, OS numerically favored capivasertib (HR 0.82; 95% CI 0.68–0.99; nominal P=.044; median 57.4 vs 46.5 months); as a descriptive analysis, it does not support a confirmatory conclusion. According to the presented abstract, the safety profile was consistent with the primary analysis, with no new safety signals.
Why it matters: with a PFS gain of about 7.5 months and no formally proven OS benefit yet, the toxicity-cost balance is uncertain; it also requires PTEN immunohistochemistry, which is scarce in the region.
Sources
- [Article] «Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281». Ann Oncol. 2026. https://www.sciencedirect.com/science/article/pii/S092375342606878X
- [Coverage] Urology Times, October 27, 2026. https://www.urologytimes.com/view/updated-capitello-281-data-show-numerical-os-benefit-with-capivasertib-in-pten-deficient-mhspc
- [Regulator] FDA, approval of capivasertib with abiraterone and prednisone for PTEN-deficient prostate cancer, June 12, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation
BPH and voiding dysfunction
5. Bipolar enucleation (BipolEP) versus TURP: noninferior at 12 months, according to the authors
[Clinical trial] [Europe]
Open-label, two-center randomized noninferiority trial (Pallauf et al., European Urology Focus, October 23; registry NCT03503721, sponsored by Salzburger Landeskliniken): 84 men with prostates of 40–150 mL, IPSS ≥15 and Qmax ≤15 mL/s or retention, randomized to bipolar enucleation or TURP; 66 were included in the primary per-protocol analysis. Median 12-month IPSS was 5 points in both arms; the authors conclude that enucleation is noninferior to TURP. Enucleation removed more tissue (38.4 vs 25.0 g) with longer operative time (86 vs 67 min) and more minor early complications (Clavien 1–2: 54% vs 28%); grade ≥3 complications (10%) occurred only after TURP.
Why it matters: a small trial, with 18 of 84 participants (21%) excluded from the per-protocol analysis and short follow-up, but it suggests enucleation can be done with the bipolar equipment many Dominican hospitals already have, without a laser.
Sources
- [Article] Pallauf M, et al. «Bipolar Enucleation of the Prostate Versus Transurethral Resection of the Prostate: A Prospective Randomized Controlled Noninferiority Trial». Eur Urol Focus. 2026. https://pubmed.ncbi.nlm.nih.gov/42919758/
- [Registry] NCT03503721, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03503721
- [Registry] NCT03503721, ClinicalTrials.gov (record viewed on Veeva CTV). https://ctv.veeva.com/study/bipolar-transurethral-enucleation-bipolep-vs-bipolar-transurethral-resection-of-the-prostate
- [Coverage] Omnicuris, October 24, 2026. https://www.omnicuris.com/medshots/daily_updates/bipolar-enucleation-vs-turp-trial-prostate-enlargement_24-Oct-26_14-18
Stones and endourology
No verifiable trials or regulatory decisions dated within the period.
Andrology, transplantation, pediatric urology and robotic surgery
No verifiable trials or regulatory decisions dated within the period.
Upcoming meetings and dates
- 46th Congress of the Société Internationale d'Urologie (SIU), Florence, Italy, November 11–14, 2026.
https://www.siu-urology.org/congress-2026/highlights - Already held during the period: ESMO Congress 2026, Madrid, October 23–27.
Ready-to-paste LinkedIn post
Monthly urology bulletin — November 6, 2026 5 verified items from the past month: ESMO 2026 and European Urology Focus. Three worth your time: • VOLGA (n=695): perioperative durvalumab + enfortumab vedotin in cisplatin-ineligible muscle-invasive bladder cancer reduced events (HR 0.51) and deaths (HR 0.58). Interim analysis of an AstraZeneca trial. • KEYNOTE-866 (n=907): adding perioperative pembrolizumab to neoadjuvant gemcitabine–cisplatin did not significantly improve EFS (HR 0.88); OS was similar (HR 1.00), despite more pathologic complete responses. • PEACE-1 at 7.7 years: abiraterone added to ADT ± docetaxel in de novo metastatic prostate cancer improved OS (HR 0.75); with ADT + docetaxel, 8-year OS 40% vs 27%. The interaction by disease volume was not significant (P=.56). Full bulletin, with a critical appraisal of each study and links to its sources: https://boletinesmedicos.com/en/urology/2026-11-06.html #Urology #ProstateCancer #BladderCancer #ESMO2026
Ready-to-paste X (Twitter) post
VOLGA: durvalumab + enfortumab vedotin in cisplatin-ineligible muscle-invasive bladder cancer cut deaths (HR 0.58). PEACE-1: abiraterone + ADT + docetaxel in metastatic prostate cancer, 8-year OS 40% vs 27%. https://boletinesmedicos.com/en/urology/2026-11-06.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.